Email this article 
Cutaneous Manifestations of Breast Cancer Patients in Combination with Capecitabine and Lapatinib Chemotherapy
Abstract
The combination of chemotherapy with lapatinib and capecitabine in human epidermal growth factor receptor 2 (HER2) positive breast cancer is quite effective. The combination of these two agents increases the risk of dermatological toxicities. A woman, 38 years old, HER2 positive breast cancer with a combination of chemotherapy agents between lapatinib and capecitabine gives an overview of skin toxicities such as acneiform eruptions, palmar-plantar erythrodysesthesia (PPE), and paronychia. Therapy, in this case, aims at clinical improvement. The combination of lapatinib and capecitabine has a side effect profile like each drug. Combined use of the two agents increases the incidence of skin side effects, including acneiform eruptions, PPE, and paronychia, compared to monotherapy. Early awareness of the side effects of chemotherapeutic agents is needed for early treatment to prevent the worsening of the condition and discontinuation of chemotherapeutic agents due to drug side effects.
Keywords
Full Text:
PDFReferences
World Health Organization (WHO). Global Cancer Observatory. 2020.
Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733–43.
Yang F, Huang X, Sun C, et al. Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population. BMC Cancer; 2020: 20, 255. https://doi.org/10.1186/s12885-020-6639-4
Ryan Q, Ibrahim A, Cohen MH, Johnson J, Ko CW, Sridhara R, et al. FDA drug approval summary: Lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist. 2008;13:1114–1119.
Madden R, Kosari S, Peterson GM, Bagheri N, Thomas J. Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review.
Int J Clin Pharmacol Ther. 2018; 56: 72-80. doi: 10.5414/CP203123.
Califano R, Tariq N, Compton S, Fitzgerald DA, Harwood CA, Lal R, et al. Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK. Drugs Oncol J. 2015;75(12):1335–48
Pinto HP, Bhat RM, Shet D, Dandekeri S. Compound mucocutaneous adverse effects of oral capecitabine in a patient. Indian Dermatol Online J. 2014;5(3):349-352. doi:10.4103/2229-5178.137804
Geay F. Physiopathology, diagnosis and treatment of breast cancer. Soin; la revue de reference infirmiere, 2013; 25-29.
Gómez HL, Neciosup S, Tosello C, Mano M. A Phase II Randomized Study of Lapatinib Combined with Capecitabine, Vinorelbine, or Gemcitabine in Patients with HER2-Positive Metastatic Breast Cancer with Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study). Clin Breast Ca. 2016; 16 (1): 38-44,
AL Agero SW, C Dusza, Andrade B, et al. Dermatologic side effects associated with the epidermal growth receptor inhibitors. J Am Acad Dermatol, 2006; 55: 657-670
Perez-Soler RL, Saltz. Cutaneous adverse effects with HER1/EGFR-targeted agents: Is there a silver lining? J Clin Oncol. 2005; 5235-5246
Kaufman B, Stein S, Casey MA, Newstat BO. Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer. Biologics. 2008;2(1):61-65. doi:10.2147/btt.s1713
Rodeck U, Jost M, Kari C, Shih DT, Lavker RM, Ewert DL, Jensen PJ. EGF-R dependent regulation of keratinocyte survival. J Cell Sci. 1997 Jan; 110 (Pt 2):113-21.
Abdullah SE, Haigentz M Jr, Piperdi B. Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management. Chemother Res Pract. 2012; 2012():351210.
Kara A, Alatas E, Dogan G, Celik SY, Tanriverdi O. A first case report of diffuse acneiform eruption caused by capecitabine in a patient with small-cell neuroendocrine lung carcinoma. J Oncol Pharm Pract. 2016 Oct;22(5):717-9. doi: 10.1177/1078155215587542. Epub 2015 May 20. PMID: 25994157
Olt S, Yalçın GG, Uysal OS, Karakeçe E, Ciftci IH. Demodex spp. Infestation in a breast-cancer patient: A case report. Niger Med J. 2013;54(5):349-350. doi:10.4103/0300-1652.122371
Ayers K, Sweeney SM, Wiss K. Pityrosporum Folliculitis: Diagnosis and Management in 6 Female Adolescents With Acne Vulgaris. Arch Pediatr Adolesc Med. 2005;159(1):64–67. doi:10.1001/archpedi.159.1.64
Ho P-HD, Cho Y-TD, Chu C-YP. Using a novel scoring system for paronychia related to oncologic treatments (SPOT) for assessing paronychia severity and its correlation with pain index and quality of life. J Eur Acad Dermatology Venereol. 2019;1(33):204–12.
Rigopoulos D, Larios G, Gregoriou S, Alevizos A. Acute and chronic paronychia. Am Fam Physician 2008;77(3):339-346.
Aw DCW, Tan EH, Chin TM, Lim HL, Lee HY, Soo RA. Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities. Asia Pac J Clin Oncol. 2018;14(1):23–31.
Vaccaro M, Barbuzza O, Guarneri F, Guarneri B. Nail and periungual toxicity following capecitabine therapy. Br J Clin Pharmacol. 2008;66(2):325-326. doi:10.1111/j.1365-2125.2008.03174.x
Capriotti K, Capriotti J, Pelletier J, Stewart K. Chemotherapy-associated paronychia treated with 2% povidone–iodine: A series of cases. Cancer Manag Res. 2017;9:225–8.
Nikolaou V, Syrigos K, Saif MW. Incidence and implications of chemotherapy-related hand-foot syndrome. Expert Opin Drug Saf. 2016;15:1625–33.
Clark AS, Vahdat LT. Chemotherapy-Induced Palmar-Plantar Erythrodysesthesia Syndrome: Etiology and Emerging Therapies. Support Cancer Ther. 2004;1:213–8
Do JE, Kim YC. Capecitabine-induced diffuse palmoplantar keratoderma: Is it a sequential event of hand-foot syndrome? Clin Exp Dermatol. 2007;32:519– 21
DOI: https://doi.org/10.18196/mmjkk.v23i1.12276
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Editorial Office:
Journal Room, G1 (Biomedic) Building, Ground Floor, Faculty of Medicine and Health Science Universitas Muhammadiyah Yogyakarta,
Jalan Lingkar Selatan (Brawijaya), Tamantirto, Kasihan, Bantul, Daerah Istimewa Yogyakarta, Indonesia
Phone: +62 274 387 656 (ext: 231)
WA : +62 811-2650-303
Website: http://journal.umy.ac.id/index.php/mm
E-mail: mmjkk@umy.university
Mutiara Medika: Jurnal Kedokteran dan Kesehatan is licensed under a Creative Commons Attribution 4.0 International License. View My Stats